BCMA-Targeted Therapies “Promising” in Multiple Myeloma

02.24.21

BCMA-Targeted Therapies “Promising” in Multiple Myeloma

by Eleanor Mayfield, ELS

$MRD Negativity “Achievable” Even in High-Risk Refractory Multiple Myeloma$

02.18.21

MRD Negativity “Achievable” Even in High-Risk Refractory Multiple Myeloma

by Eleanor Mayfield, ELS

Exact Sciences Acquires Rights to TARDIS Liquid Biopsy Technology

02.16.21

Exact Sciences Acquires Rights to TARDIS Liquid Biopsy Technology

by Eleanor Mayfield, ELS

MRD “Key Component” in Treatment Selection for Transplant-Eligible Multiple Myeloma Patients

02.10.21

MRD “Key Component” in Treatment Selection for Transplant-Eligible Multiple Myeloma Patients

by Eleanor Mayfield, ELS

Blocking a Fatty-Acid Metabolism Pathways Improves GVHD

12.01.20

Blocking a Fatty-Acid Metabolism Pathways Improves GVHD

by Alex Kadhim

MRD in Multiple Myeloma: “The Utility Is Undeniable,” Although Use in Clinical Decision Making is Premature

10.26.20

MRD in Multiple Myeloma: “The Utility Is Undeniable,” Although Use in Clinical Decision Making is Premature

by Eleanor Mayfield, ELS

Survey: Clinicians Are Assessing MRD in Multiple Myeloma, but Demur at Using It to Make Treatment Decisions

09.30.20

Survey: Clinicians Are Assessing MRD in Multiple Myeloma, but Demur at Using It to Make Treatment Decisions

by Eleanor Mayfield, ELS

“Impressive” Results for Investigational BiTEs Seen in Phase 1 Myeloma Studies

09.18.20

“Impressive” Results for Investigational BiTEs Seen in Phase 1 Myeloma Studies

by Eleanor Mayfield, ELS

Incyte Announces Recipient of Incyte Ingenuity Award

09.18.20

Incyte Announces Recipient of Incyte Ingenuity Award

by Kate Jacobson

Theme picker

Thank you to our sponsors